Fetuin-A and Its Association with Anthropometric, Atherogenic, and Biochemical Parameters and Indices among Women with Polycystic Ovary Syndrome
暂无分享,去创建一个
B. Zubelewicz-Szkodzińska | P. Jagielski | B. Hudzik | J. Nowak | Karolina Kulik-Kupka | Marzena Jabczyk
[1] D. Chlubek,et al. The Role of Oxidative Stress in the Risk of Cardiovascular Disease and Identification of Risk Factors Using AIP and Castelli Atherogenicity Indicators in Patients with PCOS , 2022, Biomedicines.
[2] M. Usta,et al. Investigating Fetuin-A and Paraoxonase-1 Activity as Markers in Polycystic Ovary Syndrome Based on Body Mass Index: A Prospective Case-Control Study , 2021, Cureus.
[3] Abbas Ali Sangouni,et al. Effect of l-carnitine supplementation on liver fat content and cardiometabolic indices in overweight/obese women with polycystic ovary syndrome: A randomized controlled trial. , 2021, Clinical nutrition ESPEN.
[4] Teresa Walczyk. Anthropometric indicators of obesity. Are the new indicators a better predictor of body fat content than BMI? , 2021, Journal of Education, Health and Sport.
[5] Wei-liang Chen,et al. Atherogenic index of plasma as predictors for metabolic syndrome, hypertension and diabetes mellitus in Taiwan citizens: a 9-year longitudinal study , 2021, Scientific Reports.
[6] Erdal Kurnaz,et al. Evaluation of the pathophysiological role of Fetuin A levels in adolescents with polycystic ovary syndrome , 2021, Journal of pediatric endocrinology & metabolism : JPEM.
[7] J. Wilczyński,et al. A body shape index (ABSI) and endometrial pathology , 2021, Women & health.
[8] G. Sesti,et al. Effects of Alpha-2-HS-glycoprotein on cognitive and emotional assessment in prediabetic and diabetic subjects. , 2020, Journal of affective disorders.
[9] H. Yıldıran,et al. Effects of fetuin-A with diverse functions and multiple mechanisms on human health. , 2020, Clinical biochemistry.
[10] N. Moradi,et al. Evaluation of lipid ratios and triglyceride-glucose index as risk markers of insulin resistance in Iranian polycystic ovary syndrome women , 2020, Lipids in health and disease.
[11] S. Atkin,et al. Dynamic Changes in Circulating Endocrine FGF19 Subfamily and Fetuin-A in Response to Intralipid and Insulin Infusions in Healthy and PCOS Women , 2020, Frontiers in Endocrinology.
[12] E. Suliga,et al. Anthropometric indices and cut-off points in the diagnosis of metabolic disorders , 2020, PloS one.
[13] A. Jan,et al. BMI Classification Percentile And Cut Off Points , 2019 .
[14] K. Marycz,et al. Pathophysiological Implication of Fetuin-A Glycoprotein in the Development of Metabolic Disorders: A Concise Review , 2019, Journal of clinical medicine.
[15] W. Rathmann,et al. Visceral adiposity index (VAI), lipid accumulation product (LAP), and product of triglycerides and glucose (TyG) to discriminate prediabetes and diabetes , 2019, Scientific Reports.
[16] A. Kerkadi,et al. Body Shape Index Is a Stronger Predictor of Diabetes , 2019, Nutrients.
[17] J. Tuomilehto,et al. Fetuin-A levels are increased in the adipose tissue of diabetic obese humans but not in circulation , 2018, Lipids in Health and Disease.
[18] F. Villarroya,et al. Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome , 2018, International journal of endocrinology.
[19] H. Hetta,et al. The adipokine Chemerin and Fetuin-A Serum Levels in Type 2 Diabetes Mellitus: Relation to Obesity and Inflammatory Markers. , 2018, The Egyptian journal of immunology.
[20] Vandana Gupta,et al. L:A ratio, Insulin resistance and metabolic risk in women with polycystic ovarian syndrome. , 2017, Diabetes & metabolic syndrome.
[21] B. Zubelewicz-Szkodzińska,et al. Usefulness of a new anthropometric indicator - VAI (Visceral Adiposity Index) in the evaluation of metabolic and hormonal disorders in women with polycystic ovary syndrome. , 2017, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[22] B. Fauser,et al. Are women with polycystic ovary syndrome at increased cardiovascular disease risk later in life? , 2017, Climacteric : the journal of the International Menopause Society.
[23] T. Esposito,et al. Quality of life in overweight (obese) and normal-weight women with polycystic ovary syndrome , 2017, Patient preference and adherence.
[24] Jianhua Zheng,et al. Obesity contributes more to increasing ApoB/ApoA1 ratio than hyperandrogenism in PCOS women aged 20–38 years in China , 2017, Experimental and therapeutic medicine.
[25] M. Budoff,et al. Fetuin-A and Risk of Diabetes Independent of Liver Fat Content: The Multi-Ethnic Study of Atherosclerosis , 2017, American journal of epidemiology.
[26] F. Casanueva,et al. Visceral and subcutaneous adipose tissue express and secrete functional alpha2hsglycoprotein (fetuin a) especially in obesity , 2017, Endocrine.
[27] F. Cirillo,et al. From Placenta to Polycystic Ovarian Syndrome: The Role of Adipokines , 2016, Mediators of inflammation.
[28] Hong Wu,et al. Analysis on endocrine and metabolic features of different phenotypes of polycystic ovary syndrome patients. , 2016, Pakistan journal of pharmaceutical sciences.
[29] Y. Iso,et al. Facilitatory effects of fetuin-A on atherosclerosis. , 2016, Atherosclerosis.
[30] H. J. Yoo,et al. Hepatokines as a Link between Obesity and Cardiovascular Diseases , 2015, Diabetes & metabolism journal.
[31] A. Altinova,et al. Serum levels of fetuin A are increased in women with gestational diabetes mellitus , 2015, Archives of Gynecology and Obstetrics.
[32] W. Zgliczyński,et al. Fetuin-A levels in lean and obese women with polycystic ovary syndrome. , 2014, Endokrynologia Polska.
[33] Y. Enli,et al. Serum Fetuin-A levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome , 2013, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[34] A. Yuksel,et al. The serum protein α2-Heremans-Schmid glycoprotein/fetuin-a concentration and carotid intima-media thickness in women with polycystic ovary syndrome. , 2013, European journal of obstetrics, gynecology, and reproductive biology.
[35] B. Pamuk,et al. Serum Fetuin-A levels in women with polycystic ovary syndrome , 2012, Archives of Gynecology and Obstetrics.
[36] G. Schernthaner,et al. Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. , 2010, The Journal of clinical endocrinology and metabolism.
[37] S. Cummings,et al. Fetuin-A and change in body composition in older persons. , 2009, The Journal of clinical endocrinology and metabolism.
[38] C. Reutelingsperger,et al. Fetuin-A protects against atherosclerotic calcification in CKD. , 2009, Journal of the American Society of Nephrology : JASN.
[39] A. Galluzzo,et al. Insulin resistance and polycystic ovary syndrome. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[40] E. Coşar,et al. Body fat composition and distribution in women with polycystic ovary syndrome , 2008, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[41] M. McCarthy,et al. Obesity and polycystic ovary syndrome , 2006, Clinical endocrinology.
[42] D. Ehrmann,et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. , 2006, The Journal of clinical endocrinology and metabolism.
[43] M. Kośmicki. Zaburzenia lipidowe u pacjentów z chorobami układu sercowo-naczyniowego. Część I: leczenie statynami , 2003 .
[44] Leslie Retnam,et al. Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. , 2003, Free radical biology & medicine.